Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Maureen Leehey and Stefan Sillau.

 
Connection Strength
 
 
 
1.107
 
  1. Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, Thompson JA, Seawalt T, Klawitter J, Sempio C, Chin G, Forman L, Fullard M, Hawkins T, Seeberger L, Newman H, Vu D, Leehey MA. Short-Term Cannabidiol with ?-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Mov Disord. 2024 May; 39(5):863-875.
    View in: PubMed
    Score: 0.220
  2. Domen CH, Sillau S, Liu Y, Leehey MA. Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds. Mov Disord. 2024 Jan; 39(1):222-223.
    View in: PubMed
    Score: 0.217
  3. Domen CH, Sillau S, Liu Y, Adkins M, Rajkovic S, Bainbridge J, Sempio C, Klawitter J, Leehey MA. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and ?9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Mov Disord. 2023 07; 38(7):1341-1346.
    View in: PubMed
    Score: 0.207
  4. Holden SK, Domen CH, Sillau S, Liu Y, Leehey MA. Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's Disease. Mov Disord Clin Pract. 2022 Apr; 9(3):340-350.
    View in: PubMed
    Score: 0.189
  5. Leehey MA, Liu Y, Hart F, Epstein C, Cook M, Sillau S, Klawitter J, Newman H, Sempio C, Forman L, Seeberger L, Klepitskaya O, Baud Z, Bainbridge J. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020; 5(4):326-336.
    View in: PubMed
    Score: 0.175
  6. Weber I, Zagona-Prizio C, Sivesind TE, Adelman M, Szeto MD, Liu Y, Sillau SH, Bainbridge J, Klawitter J, Sempio C, Dunnick CA, Leehey MA, Dellavalle RP. Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial. JMIR Dermatol. 2024 Mar 11; 7:e49965.
    View in: PubMed
    Score: 0.055
  7. Rietcheck HR, Maghfour J, Rundle CW, Husayn SS, Presley CL, Sillau SH, Liu Y, Leehey MA, Dunnick CA, Dellavalle RP. A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids. Dermatology. 2021; 237(6):872-877.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)